TXN 10128
Alternative Names: TXN-10128Latest Information Update: 07 Sep 2023
At a glance
- Originator Txinno Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Jul 2023 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in South Korea (PO) (NCT05978492)
- 27 Jul 2023 Txinno Biosciences plans a phase I trial for Solid tumours (Late stage, Second line therapy or greater, Metastatic disease, Inoperable/Unresectable, In infants, In neonates, In Children, In adolescent, In adults) (PO, Capsule) (NCT05978492)
- 01 May 2023 Txinno Bioscience's IND application was approved in South Korea for Cancer (Txinno Bioscience pipeline, July 2023)